- Home
- RCKT vs GOSS Comparison
RCKT vs GOSS Comparison
Compare RCKT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- GOSS
- Stock Information
- Founded
- RCKT 1999
- GOSS 2015
- Country
- RCKT United States
- GOSS United States
- Employees
- RCKT N/A
- GOSS N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- GOSS Health Care
- Exchange
- RCKT Nasdaq
- GOSS Nasdaq
- Market Cap
- RCKT 328.6M
- GOSS 347.8M
- IPO Year
- RCKT N/A
- GOSS 2019
- Fundamental
- Price
- RCKT $3.28
- GOSS $2.47
- Analyst Decision
- RCKT Buy
- GOSS Strong Buy
- Analyst Count
- RCKT 13
- GOSS 4
- Target Price
- RCKT $12.96
- GOSS $8.50
- AVG Volume (30 Days)
- RCKT 6.0M
- GOSS 3.1M
- Earning Date
- RCKT 08-07-2025
- GOSS 08-05-2025
- Dividend Yield
- RCKT N/A
- GOSS N/A
- EPS Growth
- RCKT N/A
- GOSS N/A
- EPS
- RCKT N/A
- GOSS N/A
- Revenue
- RCKT N/A
- GOSS $40,237,000.00
- Revenue This Year
- RCKT N/A
- GOSS N/A
- Revenue Next Year
- RCKT $108.43
- GOSS $30.65
- P/E Ratio
- RCKT N/A
- GOSS N/A
- Revenue Growth
- RCKT N/A
- GOSS N/A
- 52 Week Low
- RCKT $2.19
- GOSS $0.66
- 52 Week High
- RCKT $22.01
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- RCKT 51.17
- GOSS 68.08
- Support Level
- RCKT $2.88
- GOSS $2.38
- Resistance Level
- RCKT $3.74
- GOSS $2.65
- Average True Range (ATR)
- RCKT 0.27
- GOSS 0.15
- MACD
- RCKT 0.02
- GOSS 0.03
- Stochastic Oscillator
- RCKT 35.43
- GOSS 76.67
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.